Press release
Post-Bariatric Hypoglycemia Market to Surpass USD 341.83 million by 2031 Amid Rising Bariatric Surgery Rates and Diagnostic Advances
Post-Bariatric Hypoglycemia Market
Post-Bariatric Hypoglycemia (PPH), a condition marked by recurrent low blood sugar following weight-loss surgery, is increasingly recognized as a serious complication demanding medical attention. According to DataM Intelligence analysis, the global PPH market was valued at approximately USD 206.55 million in 2023 and is projected to reach USD 341.83 million by 2031, representing a compound annual growth rate (CAGR) of 6.5% during 2024-2031. This growth is propelled by the rapidly increasing number of bariatric procedures and a surge in research and development focused on novel therapeutics and diagnostics.
Get an Exclusive Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/post-bariatric-hypoglycemia-market?ophp
Post-Bariatric Hypoglycemia Market Drivers
Based on findings from DataM Intelligence, several key factors are fueling growth in the PPH market:
• Increasing Bariatric Surgery Rates: As obesity prevalence rises worldwide, more individuals undergo gastric bypass and sleeve gastrectomy-procedures associated with a higher risk of post-operative hypoglycemia.
• Enhanced Diagnostic Tools: Continuous glucose monitoring (CGM) systems and improved lab tests are enabling earlier identification and better oversight of PPH episodes.
• Emerging Pharmacological Therapies: Novel medications-such as GLP-1 receptor modulators and diazoxide analogs-are being tested specifically for PPH, offering more effective management strategies.
• Rising Clinical Awareness: Gastroenterologists and endocrinologists are now more alert to PPH, leading to increased testing, diagnosis, and treatment plans.
• Supportive Reimbursement Policies: Healthcare payers are recognizing the cost-effectiveness of early diagnosis and treatment, adding coverage for CGM devices and off-label PPH medications.
Market Segments Overview:
By Drug Class (Glucosidase Inhibitor, Somatostatin Agonist, Calcium Ion Influx Inhibitor, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
Regional Outlook of Post-Bariatric Hypoglycemia Market
North America
North America holds over 50% of global PPH market revenue, according to DataM Intelligence, supported by high bariatric surgery rates, widespread access to advanced glucose monitoring, and active clinical trial networks.
Europe
Europe is the second-largest market, driven by national obesity programs in the UK, France, and Germany. According to DataM Intelligence, these countries also offer reimbursement for CGM devices used post-bariatric surgery, enhancing PPH patient management.
Asia-Pacific
The Asia-Pacific region is the fastest-growing segment. Countries like Japan, South Korea, and Australia are raising bariatric procedure funding and supporting early-generation diagnostic tools. Japan's Ministry of Health has recently extended support for CGM use after bariatric surgeries, facilitating better PPH outcomes.
Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/post-bariatric-hypoglycemia-market?ophp
Market Players:
Teva Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Orchid Chemicals & Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals, Zee Laboratories Ltd., Bayer AG, Eiger BioPharmaceuticals, and Vogenx among others.
Industry Momentum: Collaborations & Growth 2024-2025
• Dexcom & Bariatric Research Alliance (May 2024): Partnered to develop CGM-guided postoperative monitoring protocols for PPH patients, improving early detection.
• Novo Nordisk & GI Therapeutics (October 2024): Launched a joint clinical trial exploring off-label use of GLP-1 receptor agonists to reduce post-meal hypoglycemic episodes in PPH patients.
• AbbVie Acquisition of Rare Disease Biotech (March 2025): Acquired a small biotech focusing on diazoxide analogs, enhancing its portfolio with new PPH-targeted therapy.
• Medtronic & EndoSense Diagnostics (July 2024): Co-developed abdominal wearable sensors for real-time monitoring of postprandial glucose dips to alert PPH patients before symptomatic episodes.
• Sanofi & NIH PPH Study (January 2025): Partnered to fund a pivotal U.S. study evaluating the efficacy of novel antiglycemic compounds in reducing the frequency and severity of PPH.
Latest News of USA (2025)
In March 2025, the U.S. Centers for Medicare & Medicaid Services (CMS) approved national coverage for CGM use in patients showing symptoms of post-bariatric hypoglycemia, recognizing the device's value in preventing hospital admissions due to severe hypoglycemic spells. Additionally, the American Society for Metabolic and Bariatric Surgery updated its clinical guidelines to recommend pre-operative CGM screening and post-surgical follow-up in patients with suspected PPH.
Latest News of Japan (2025)
In April 2025, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) granted priority review for a novel diazoxide analog aimed at treating PPH, following promising phase II trial data showing reduced hypoglycaemic episodes in 75% of treated patients. Furthermore, the Japanese Society of Bariatric Surgeons endorsed mandatory postoperative glucose monitoring in all gastric bypass patients, reflecting growing awareness of PPH and Japan's commitment to improved surgical outcomes.
Conclusion
According to DataM Intelligence analysis, the Post-Bariatric Hypoglycemia market stands at a critical inflection point-driven by increasing bariatric surgery rates, advanced diagnostic tools, emerging therapies, and aligned regulatory efforts. With strong growth momentum, cross-sector partnerships, and clinical guideline updates in key regions, PPH is moving from an under-recognized surgical complication to a strategic focus for healthcare providers, device innovators, and pharmaceutical developers. As market attention grows, patients and clinicians alike stand to benefit from safer, more personalized outcomes in the post-bariatric journey.
Looking for the full report? Get it here: https://www.datamintelligence.com/buy-now-page?report=post-bariatric-hypoglycemia-market?ophp
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Post-Bariatric Hypoglycemia Market to Surpass USD 341.83 million by 2031 Amid Rising Bariatric Surgery Rates and Diagnostic Advances here
News-ID: 4078065 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Left Ventricular Assist Devices (LVADs) Market to Surpass $2.67 Billion by 2033, …
Left Ventricular Assist Devices (LVADs) are mechanical circulatory support systems designed to assist the left ventricle in pumping blood in patients with advanced heart failure. Initially used as a bridge to transplantation, LVADs are now increasingly prescribed for long-term support. According to DataM Intelligence, the global LVAD market was valued at approximately USD 1.31 billion in 2024 and is projected to reach USD 2.67 billion by 2033, growing at a…
Hyper-Personalized Medicine Market to Hit USD 505.26 by 2033, Driven by AI Genom …
Hyper-personalized medicine delivers treatments tailored to an individual's unique genetic profile, lifestyle, and environment-far beyond traditional precision medicine. According to DataM Intelligence analysis, the global hyper-personalized medicine market was valued at approximately USD 256.72 billion in 2024 and is projected to reach USD 505.26 billion by 2033, growing at a robust compound annual growth rate (CAGR) of 7.9% during 2025-2033. Fueled by advances in genomics, AI-driven analytics, and digitized health…
Mobile Water Treatment Market to Grow at a CAGR of 7.2% During 2024-2031 on Risi …
Mobile Water Treatment Market Overview
Mobile water treatment systems are portable units that purify water on-site which is gaining traction in municipalities, industrial settings, military operations, and disaster relief scenarios. According to DataM Intelligence analysis, the global mobile water treatment market is demonstrating a strong compound annual growth rate (CAGR) of 7.2% during 2024-2031. This surge underscores the global need for reliable, transportable solutions to ensure safe water access during emergencies…
Tyrosine Kinase Inhibitors Market for Targeted Oncology Therapies | Driven by Bi …
Tyrosine Kinase Inhibitors Market reached US$ 51.03 billion in 2023 and is expected to reach US$ 82.47 billion by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031.
The Tyrosine Kinase Inhibitors Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay…
More Releases for PPH
PayPerHead.net launches PPH review site
New Industry reviewing portal will encompass all PPH companies and assess the benefits of each PPH software service.
29.06.2020 – San Jose, Costa Rica
PayPerHead.net – the advanced pay per head bookie service supporting industry growth at all levels – has announced its launch of a review site which will compare the features and benefits of all pay per head (PPH) providers on the market.
The new review platform will seek to break…
Polypropylene Homopolymer (PPH) Resin Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Polypropylene Homopolymer (PPH) Resin market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Polypropylene Homopolymer (PPH) Resin market by key players, product type, applications and regions,etc.
The main objective of this market research is to help the readers understand the structure of Polypropylene Homopolymer (PPH) Resin market,…
PPH Devices Market : The Next Big Thing in Medical Device Industry
Post-partum Hemorrhage (PPH) Devices Market Report, published by Allied Market Research, was valued at $637 million in 2015, and is expected to garner $906 million by 2022, registering a CAGR of 5.2% during the period 2016 - 2022.The Uterine balloon tamponade is expected to remain the highest revenue-generating segment throughout the forecast period.
Download Request Sample Copy: https://www.alliedmarketresearch.com/request-sample/1676
The factors that are expected to drive the growth of the PPH market are:…
PricePerPlayer.com Adds 111 Casino Games to their Sportsbook PPH Services
The Sportsbook Pay Per Head industry enjoyed doubled digit growth in 2017 thanks to an increase in online gambling popularity. PricePerPlayer.com itself showed extensive profits in its first quarter thanks to the success of its expansion into the Asian-Market. In response to this growth, the software development company increased the number of casino games for their Sportsbook PPH Services.
In order to continue the growth of their Sportsbook Pay Per…
Global Postpartum Hemorrhage (PPH) Treatment Devices Market is Primarily being D …
The global postpartum hemorrhage treatment devices market is progressing at a CAGR of 4.9% within a forecast period of 2015 to 2023. Owing to this positive growth rate, the market is expected to reach US$926.1 mn before the end of 2023. The global postpartum hemorrhage treatment devices market was recorded at US$604.4 mn in 2014, according to a research report released by Transparency Market Research. The report, titled “Postpartum Hemorrhage…
Global Postpartum Hemorrhage (PPH) Treatment Devices Industry 2016 Market Resear …
Summary
The Global Postpartum Hemorrhage (PPH) Treatment Devices Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Postpartum Hemorrhage (PPH) Treatment Devices industry.
Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Postpartum Hemorrhage (PPH) Treatment Devices market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’…
